Bio-Path Holdings Inc. (BPTH) had a good day on the market for Friday November 01 as shares jumped 5% to close at $11.35. About 48,116 shares traded hands on 476 trades for the day, compared with an average daily volume of n/a shares out of a total float of 2.88 million. After opening the trading day at $10.83, shares of Bio-Path Holdings Inc. stayed within a range of $11.78 to $10.83.
With today’s gains, Bio-Path Holdings Inc. now has a market cap of $32.73 million. Shares of Bio-Path Holdings Inc. have been trading within a range of $73.52 and $1.61 over the last year, and it had a 50-day SMA of $n/a and a 200-day SMA of $n/a.
Bio-Path Holdings Inc is a United States based clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. The company’s lead drug candidate, prexigebersen, is in the efficacy portion of a Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and in combination with decitabine. The other drug candidates of the company are BP1002 and BP1003.
Bio-Path Holdings Inc. is based out of Bellaire, TX and has some 8 employees. Its CEO is Peter H. Nielsen.
Bio-Path Holdings Inc. is also a component of the Russell 2000. The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It’s maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.
Russell’s indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It’s a simple approach that gives a broad, unbiased look at the small-cap market as a whole.
